Does alpha-lipoic acid decrease hepatic lipogenesis through adenosine monophosphate-activated protein kinase ( AMPK ) -dependent and AMPK-independent pathways?
These results show that ALA prevents fatty liver disease through multiple mechanisms, and suggest that ALA can be used to prevent the development and progression of nonalcoholic fatty liver disease in patients with insulin resistance.
Patients receiving neoadjuvant TKI therapy prior to CN experienced more high grade surgical complications than patients who underwent primary CN. Potential for increased high grade surgical complications requires further investigation and may impact pretreatment counseling.